Drug Profile
Influenza A virus vaccine H7N1 - GSK
Alternative Names: GSK-2789868A; GSK-2789869ALatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H7N1 subtype
Most Recent Events
- 29 Feb 2016 No recent reports on development identified - Phase-I for Influenza-A virus H7N1 subtype (Prevention) in USA, Canada (IM)
- 29 Feb 2016 No recent reports on development identified - Phase-II for Influenza-A virus H7N1 subtype (In the elderly, Prevention) in USA, Canada (IM)
- 01 Oct 2014 GlaxoSmithKline completes a phase I trial for Influenza-A virus H7N1 subtype (prevention) in Canada and USA (NCT01934127)